文献速递临床免疫临床生化质量管理与危急值

儿童尿液药物筛查直接采用LC-MS/MS可揭示免疫分析假阴性

Direct-to-definitive urine drug screening in children unmasks false-negative immunoassay screening.
PubMed 文献 · Clin Chim Acta · 2026-06-01

本研究评估儿童尿液免疫分析药物筛查的假阴性率,采用LC-MS/MS直接检测与免疫分析对照。在125份LC-MS/MS弱阳性标本中,90%含免疫分析未检出的目标物质;145份免疫分析阴性标本中,11%含免疫分析漏检的目标物质,23%含免疫分析未覆盖物质。结论:4-11%的儿童尿标本含免疫分析漏检的目标物质,建议直接采用LC-MS/MS筛查以降低假阴性。

要点

  • 125份LC-MS/MS弱阳性尿中90%含免疫分析漏检的目标物质。
  • 145份免疫分析阴性尿中11%含漏检目标物,23%含未覆盖物质。
  • 直接LC-MS/MS筛查可减少免疫分析假阴性导致的儿童安全风险。

核心结论

  • 儿童尿液免疫分析药物筛查存在4-11%的目标物质假阴性,另约四分之一可能含免疫分析未覆盖物质,直接LC-MS/MS筛查可最小化假阴性。

研究设计与样本

  • 研究在St. Louis儿童实验室进行,采用直接LC-MS/MS筛查方法;正向分析125份弱阳性尿标本(占五个月3000份筛查的4%),反向分析145份来自五种儿科设置的免疫分析阴性尿标本。

主要发现

  • 125份LC-MS/MS阳性样本中,112份(90%)含至少一种免疫分析未检出的目标物质,最常漏检甲基苯丙胺和苯甲酰爱康宁。
  • 145份免疫分析阴性样本中,LC-MS/MS检出16份(11%)含免疫分析漏检的目标物质,34份(23%)含免疫分析未覆盖的物质。

关键数值与推荐

  • 原文未报告具体阈值、剂量、P值等数值,仅报告了上述比例。

临床怎么用

  • 对于儿童尿液药物筛查,直接采用LC-MS/MS方法可减少免疫分析假阴性,避免因漏检导致儿童被 discharge 到不安全环境。

局限性

  • 原文未明确报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Routine urine drug screening is performed using immunoassays. False-positive immunoassay results are well documented and confirmatory testing is essential. False-negative rates have not been rigorously quantified. Our study estimates the false-negative rate of immunoassay screening in a pediatric population. METHODS: Drug screening in the St. Louis Children's laboratory employs a broad spectrum direct to LC-MS/MS approach. We selected 125 urine specimens over five months (4% of 3000 screens), that were weakly positive for amphetamines, benzoylecgonine, THC, opiates, fentanyl, benzodiazepines, and methadone using LC-MS/MS. These specimens were reanalyzed by immunoassay on a Roche Cobas platform (forward approach). Second, we collected 145 negative urine specimens from five pediatric settings using immunoassay platforms including Viva-ProE (Siemens), Vitros (Ortho), Atellica (Siemens) and Cobas (Roche). These specimens were subjected to our local LC-MS/MS analysis (reverse approach). RESULTS: Among the 125 LC-MS/MS positive samples, 112 (90%) contained at least one substance that was targeted but not detected by immunoassay. The most frequently missed substances were methamphetamine and benzoylecgonine. Among the 145 negative urine specimens from routine immunoassay, LC-MS/MS identified substances in 16 (11%) that were targeted and missed by immunoassay and identified substances in 34 (23%) that were not covered by immunoassay. CONCLUSIONS: Our study indicates that 4-11% of pediatric urine specimens contain substances targeted and missed by conventional immunoassays. Another quarter may contain substances not covered by immunoassay. These false negatives can lead to the discharge of a child into an unsafe environment. Direct to LC-MS/MS screening acts to minimize false-negative immunoassay drug screens.

来源:Clin Chim Acta,查看原文。版权归原作者所有。

引用

  1. Lin Y, El-Khoury JM, Garg UC, et al. Direct-to-definitive urine drug screening in children unmasks false-negative immunoassay screening. Clin Chim Acta. 2026. PMID: 42229707. doi:10.1016/j.cca.2026.121136

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。